ArticleJournal of family & community medicine
Patterns and experiences of patients with undifferentiated lymphocytosis referred by primary care physicians in Canada.
Article in Journal of family & community medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe assessed 93 hematology referrals of patients with undifferentiated lymphocytosis, focusing on patient experience and costs for both patients and the healthcare system. MATERIALS AND
methodsWe conducted a retrospective, observational cohort study at the Royal Victoria Health Center in Barrie, Ontario, and the Hudson Regional Cancer Program, Canada. Data included the nature of referrals (primary vs. secondary lymphocytosis), flow cytometry (FC)-based diagnosis, number of visits, time spent, healthcare costs, and patient experience through anonymous questionnaires.
resultsNinety-four percent of patients were referred by their family physicians. FC results revealed that 56% of patients had primary lymphocytosis. The remaining cases were secondary lymphocytosis, with 90% of secondary cases being smoking-related. Only two patients required therapy for a newly diagnosed lymphoproliferative disorder. The average number of visits in 2023 was 1.98; 20% of patients spending 3 h or more per visit, including travel and appointment time. The reason for referral was explained to 80% of patients. While 50% of patients were nervous about attending the cancer center, over 90% felt reassured after the initial hematology consultation and found the information clear and satisfactory. However, 30% of patients reported that the visits were both financially draining and time-consuming. The total healthcare cost in 2023 was $758.42 per patient, with the total expense of $31,095 for cases of secondary lymphocytosis that did not require referral.
conclusionThese findings highlight that implementing FC in family practice can help distinguish primary from secondary lymphocytosis, reducing unnecessary hematology referrals, and potentially lowering healthcare costs, saving time, and reducing patient stress. This approach could lead to improved efficiency in the delivery of care and better utilization of healthcare resources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.